HK1210422A1 - Compositions and methods for treating cutaneous scarring - Google Patents

Compositions and methods for treating cutaneous scarring Download PDF

Info

Publication number
HK1210422A1
HK1210422A1 HK15111211.3A HK15111211A HK1210422A1 HK 1210422 A1 HK1210422 A1 HK 1210422A1 HK 15111211 A HK15111211 A HK 15111211A HK 1210422 A1 HK1210422 A1 HK 1210422A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treating cutaneous
cutaneous scarring
protein kinase
Prior art date
Application number
HK15111211.3A
Other languages
English (en)
Chinese (zh)
Inventor
Cynthia Lander
Colleen Brophy
Caryn Peterson
Original Assignee
Moerae Matrix, Inc.
Cynthia Lander
Colleen Brophy
Caryn Peterson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix, Inc., Cynthia Lander, Colleen Brophy, Caryn Peterson filed Critical Moerae Matrix, Inc.
Publication of HK1210422A1 publication Critical patent/HK1210422A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15111211.3A 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring HK1210422A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261699160P 2012-09-10 2012-09-10
US61/699,160 2012-09-10
US13/829,876 2013-03-14
US13/829,876 US20140072613A1 (en) 2012-09-10 2013-03-14 Compositions and Methods for Treating Cutaneous Scarring
PCT/US2013/059060 WO2014040074A2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Publications (1)

Publication Number Publication Date
HK1210422A1 true HK1210422A1 (en) 2016-04-22

Family

ID=50233502

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111211.3A HK1210422A1 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring
HK15111150.6A HK1210414A1 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15111150.6A HK1210414A1 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Country Status (14)

Country Link
US (1) US20140072613A1 (https=)
EP (1) EP2892546A4 (https=)
JP (1) JP6247692B2 (https=)
KR (1) KR102040710B1 (https=)
CN (1) CN105120886A (https=)
AU (1) AU2013312120B2 (https=)
CA (1) CA2884264A1 (https=)
GB (1) GB2520897B (https=)
HK (2) HK1210422A1 (https=)
MX (1) MX368878B (https=)
NZ (1) NZ705743A (https=)
RU (2) RU2705211C2 (https=)
SG (1) SG11201501818VA (https=)
WO (1) WO2014040074A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
CA2746527A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
BR112012024049A2 (pt) 2010-03-24 2017-03-01 Rxi Pharmaceuticals Corp interferência de rna em indicações dérmicas e fibróticas
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
GB2524707B (en) 2013-01-09 2020-04-22 Int Stem Cell Corporation Small molecules that promote skin regeneration
WO2015084897A2 (en) * 2013-12-02 2015-06-11 Mirimmune, Llc Immunotherapy of cancer
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016112292A1 (en) * 2015-01-08 2016-07-14 Moerae Matrix, Inc. Formulation of mk2 inhibitor peptides
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
CN104689301A (zh) * 2015-03-27 2015-06-10 吴开刚 一种祛除妊娠纹的药物及其制备方法
JP7187310B2 (ja) * 2015-10-08 2022-12-12 エーエムディー セラピューティックス エルエルシー Ｖｅｇｆ阻害剤の局所投与による皮膚障害の処置
CN105709270B (zh) * 2016-03-18 2019-01-01 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
JP6815782B2 (ja) * 2016-07-29 2021-01-20 小林製薬株式会社 α−ＳＭＡ産生抑制剤
US11697813B2 (en) 2016-10-30 2023-07-11 Sirnaomics, Inc. Pharmaceutical compositions and methods of use for activation of human fibroblast and myofibroblast apoptosis
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
CN111163784B (zh) * 2017-09-01 2024-07-26 黄玲惠 用于治疗蟹足肿的药物组合物及其用途
US10485755B1 (en) * 2018-02-05 2019-11-26 Wade Cheng Formulation and method for treatment of non-acne scars
CN112074596A (zh) * 2018-02-09 2020-12-11 亥姆霍兹慕尼黑-德国健康与环境研究中心(有限公司) 监测疤痕形成的装置和方法
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
ES2980620T3 (es) 2018-05-16 2024-10-02 Univ Leland Stanford Junior Administración controlada en hidrogel de inhibidor de la cinasa de adhesión focal para disminuir la formación de cicatrices
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
WO2020210382A1 (en) * 2019-04-08 2020-10-15 The General Hospital Corporation Enhancement of melanocyte migration using rock inhibitors
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
CN114072163A (zh) * 2019-05-09 2022-02-18 芝加哥大学 皮肤伤口愈合和瘢痕预防的新材料
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179B (zh) * 2019-12-19 2021-04-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
KR102584738B1 (ko) * 2020-01-17 2023-10-06 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
US12360428B2 (en) * 2020-04-13 2025-07-15 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法
CN113143524A (zh) * 2021-04-13 2021-07-23 王伟 一种用于构建微创兔膝关节炎模型的穿刺系统
CN117295512A (zh) * 2021-05-03 2023-12-26 爱恩斯生物有限公司 用于改善瘢痕和瘢痕瘤的包含zag衍生的肽的组合物
WO2023009439A1 (en) * 2021-07-30 2023-02-02 The Board Of Trustees Of The Leland Stanford Junior University Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
MX2024008704A (es) 2022-01-14 2024-07-22 Shanghai Hansoh Biomedical Co Ltd Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este.
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
KR102696817B1 (ko) * 2023-07-06 2024-08-21 주식회사 아루다 히알루론산, 프로테오글리칸, 글리코사미노글리칸, 아텔로콜라겐, 베타글루칸, 유비퀴논 및 비타민 e를 포함하는 에스테틱 조성물 및 이의 제조 방법
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2200557C1 (ru) * 2001-11-23 2003-03-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н.Федорова Способ лечения гипертрофических и келоидных рубцов
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
DK2617431T3 (en) 2007-01-10 2017-07-10 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and applications therefor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
WO2009021137A2 (en) * 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CA2699868A1 (en) * 2007-09-19 2009-03-26 Surmodics, Inc. Biocompatible foams, systems, and methods
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
CN102256613B (zh) * 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US8593698B2 (en) * 2009-02-26 2013-11-26 Hewlett-Packard Development Company, L.P. Void pantographs and methods for generating the same using at least one test void pantograph
US9890195B2 (en) * 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
CA2802880C (en) * 2010-06-18 2019-09-24 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
US9072706B2 (en) * 2010-12-14 2015-07-07 University Of Rochester Chimeric fibronectin matrix mimetics and uses therof
KR101697396B1 (ko) * 2011-02-02 2017-01-17 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법

Also Published As

Publication number Publication date
KR20150100615A (ko) 2015-09-02
GB2520897B (en) 2020-07-01
US20140072613A1 (en) 2014-03-13
GB201505972D0 (en) 2015-05-20
CN105120886A (zh) 2015-12-02
EP2892546A4 (en) 2016-07-13
RU2705211C2 (ru) 2019-11-06
CA2884264A1 (en) 2014-03-13
JP2015533798A (ja) 2015-11-26
WO2014040074A3 (en) 2014-06-26
SG11201501818VA (en) 2015-04-29
WO2014040074A2 (en) 2014-03-13
JP6247692B2 (ja) 2017-12-13
HK1210414A1 (en) 2016-04-22
EP2892546A2 (en) 2015-07-15
AU2013312120A1 (en) 2015-03-26
AU2013312120B2 (en) 2018-04-19
GB2520897A (en) 2015-06-03
RU2015113011A (ru) 2016-11-10
NZ705743A (en) 2018-08-31
MX368878B (es) 2019-10-21
KR102040710B1 (ko) 2019-11-05
RU2019126644A (ru) 2019-09-19
MX2015003075A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
HK1210422A1 (en) Compositions and methods for treating cutaneous scarring
WO2014062720A3 (en) Methods of treating cancer
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
NZ611108A (en) Methods of treating fgf21-associated disorders
MX2013004491A (es) Boronatos como inhibidores de arginasa.
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
HK1205941A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
MY162146A (en) Pharmaceutical composition
WO2009121872A3 (en) Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
HK1206726A1 (en) Imidazotriazinone compounds
WO2011121576A3 (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
HK1204928A1 (en) Inhibitors of the notch signalling pathway and secretion for use in medicine
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2011101634A3 (en) Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
HK1221425A1 (zh) 芋螺毒素(conotoxin)肽，其医药组合物和用途
EP4613333A3 (en) Pharmaceutical compositions comprising akt protein kinase inhibitors
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2014110353A9 (en) Notch ligand bound biocompatible substrates and their use in bone formation
EP3581653A3 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents